Essential Arterial Hypertension Clinical Trial
Official title:
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan Cilexetil + Chlorthalidone (16mg + 12.5mg and 16mg + 25mg) Compared With HYZAAR® in Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02521233 -
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
|
Phase 3 | |
Completed |
NCT04927299 -
Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension
|
Phase 3 | |
Not yet recruiting |
NCT02493322 -
Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
|
Phase 3 |